Gregory Conn - PDS Biotechnology Chief Scientific Officer
| EU6 Stock | EUR 1.67 0.09 5.70% |
Insider
Gregory Conn is Chief Scientific Officer of PDS Biotechnology Corp since 2019.
| Age | 68 |
| Tenure | 6 years |
| Phone | 800 208 3343 |
| Web | https://www.pdsbiotech.com |
PDS Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.2487) % which means that it has lost $0.2487 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.488) %, meaning that it generated substantial loss on money invested by shareholders. PDS Biotechnology's management efficiency ratios could be used to measure how well PDS Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yuval Baruch | Magic Software Enterprises | 56 | |
| Heino Erdmann | Easy Software AG | 56 | |
| Rainer Berndt | Easy Software AG | N/A | |
| Pamela Coe | Liberty Broadband | 63 | |
| Guy Bernstein | Magic Software Enterprises | 55 | |
| Gerald Rdiger | Easy Software AG | N/A | |
| Courtnee Chun | Liberty Broadband | 48 | |
| Renee JD | Liberty Broadband | 49 | |
| Andreas Zipser | Easy Software AG | N/A | |
| Christoph Khne | Easy Software AG | N/A | |
| Thomas Cziesla | Easy Software AG | N/A | |
| Nhi Stein | Easy Software AG | N/A | |
| Arik Faingold | Magic Software Enterprises | 46 | |
| Hanan MBA | Magic Software Enterprises | 71 | |
| Birgit Eijkhout | Easy Software AG | N/A | |
| Arik Kilman | Magic Software Enterprises | 70 | |
| Asaf Berenstin | Magic Software Enterprises | 45 | |
| Ben Oren | Liberty Broadband | N/A | |
| Katherine Jewell | Liberty Broadband | N/A | |
| Stephan Pauler | Easy Software AG | N/A | |
| Yuval Lavi | Magic Software Enterprises | 54 | |
Management Performance
| Return On Equity | -0.49 | |||
| Return On Asset | -0.25 |
PDS Biotechnology Corp Leadership Team
Elected by the shareholders, the PDS Biotechnology's board of directors comprises two types of representatives: PDS Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PDS. The board's role is to monitor PDS Biotechnology's management team and ensure that shareholders' interests are well served. PDS Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PDS Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Otis Brawley, Director | ||
| Joe Dervan, VP RD | ||
| Deanne Randolph, VP Relations | ||
| Gregory Conn, Chief Scientific Officer | ||
| Spencer JD, Sr Counsel | ||
| Nathalie Riebel, VP Operations | ||
| Janetta Trochimiuk, Controller | ||
| Stephen Glover, Independent Chairman of the Board | ||
| Lauren Wood, Chief Medical Officer | ||
| Richard Sykes, Independent Director | ||
| Gregory Freitag, Independent Director | ||
| Seth Voorhees, Chief Financial Officer | ||
| Sanjay Zaveri, Sr Devel | ||
| DeLyle Bloomquist, Independent Director | ||
| Kamil AliJackson, Independent Director | ||
| Michael King, Interim Chief Financial Officer | ||
| Frank BeduAddo, President, Chief Executive Officer, Director | ||
| Lauren MD, Chief Officer | ||
| Ilian Iliev, Director | ||
| Matthew CPA, Principal CFO |
PDS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PDS Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 189.69 M | |||
| Shares Outstanding | 28.89 M | |||
| Shares Owned By Insiders | 14.20 % | |||
| Shares Owned By Institutions | 23.77 % | |||
| Price To Earning | 23.42 X | |||
| Price To Book | 5.63 X | |||
| EBITDA | (21.43 M) | |||
| Net Income | (16.92 M) |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Additional Information and Resources on Investing in PDS Stock
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.